I think if the long awaited licensing deal with ICL doesn’t contain an upfront payment like biotechs get when they licence out, or at least a placement to ICL to raise capital, then I think it will be a worry. The last thing the stock needs is another investor presentation, or another trip down under telling us nothing new or even another webcast. Just focus resources on delivering!
I think if the long awaited licensing deal with ICL doesn’t...
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AJX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.74M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 334317 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 05/07/2024 (20 minute delay) ? |
| AJX (ASX) Chart |
Day chart unavailable